WO2006021930A2 - Aphrodisiac herbal composition for a female comprising epimedium grandiflorum, turnera diffusa var. aphrodisiaca, ilex paraguariensis and smilax spp - Google Patents
Aphrodisiac herbal composition for a female comprising epimedium grandiflorum, turnera diffusa var. aphrodisiaca, ilex paraguariensis and smilax spp Download PDFInfo
- Publication number
- WO2006021930A2 WO2006021930A2 PCT/IB2005/052768 IB2005052768W WO2006021930A2 WO 2006021930 A2 WO2006021930 A2 WO 2006021930A2 IB 2005052768 W IB2005052768 W IB 2005052768W WO 2006021930 A2 WO2006021930 A2 WO 2006021930A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- aphrodisiac
- female
- extract
- aphrodisiaca
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 75
- 230000002509 aphrodisiac effect Effects 0.000 title claims abstract description 29
- 239000003048 aphrodisiac agent Substances 0.000 title claims abstract description 18
- 244000188472 Ilex paraguariensis Species 0.000 title claims abstract description 11
- 235000003368 Ilex paraguariensis Nutrition 0.000 title claims abstract description 11
- 241001016310 Epimedium grandiflorum Species 0.000 title claims abstract description 9
- 244000062172 Turnera diffusa var. aphrodisiaca Species 0.000 title claims abstract description 7
- 241000605422 Asparagus asparagoides Species 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 43
- 241000196324 Embryophyta Species 0.000 claims abstract description 17
- 240000005739 Eurycoma longifolia Species 0.000 claims abstract description 16
- 235000008100 Ginkgo biloba Nutrition 0.000 claims abstract description 13
- 244000194101 Ginkgo biloba Species 0.000 claims abstract description 13
- 239000011236 particulate material Substances 0.000 claims abstract description 13
- 241001559692 Eriosema Species 0.000 claims abstract description 11
- 240000002493 Smilax officinalis Species 0.000 claims abstract description 10
- 235000008981 Smilax officinalis Nutrition 0.000 claims abstract description 10
- 241000735552 Erythroxylum Species 0.000 claims abstract description 9
- 244000042430 Rhodiola rosea Species 0.000 claims abstract description 8
- 235000003713 Rhodiola rosea Nutrition 0.000 claims abstract description 7
- 241001521901 Tribulus lanuginosus Species 0.000 claims abstract description 6
- 230000001568 sexual effect Effects 0.000 claims description 15
- 239000002775 capsule Substances 0.000 claims description 10
- 240000000143 Turnera diffusa Species 0.000 claims description 5
- 235000004952 turnera diffusa Nutrition 0.000 claims description 5
- 241001165494 Rhodiola Species 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000013355 food flavoring agent Nutrition 0.000 claims description 4
- 235000009206 Turnera diffusa Nutrition 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 239000013618 particulate matter Substances 0.000 claims 3
- 238000011282 treatment Methods 0.000 abstract description 13
- 230000035946 sexual desire Effects 0.000 abstract description 8
- 230000037007 arousal Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 description 13
- 230000001976 improved effect Effects 0.000 description 8
- 201000001881 impotence Diseases 0.000 description 5
- 208000010228 Erectile Dysfunction Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 201000001880 Sexual dysfunction Diseases 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 240000000759 Lepidium meyenii Species 0.000 description 2
- 235000000421 Lepidium meyenii Nutrition 0.000 description 2
- GMBQZIIUCVWOCD-WWASVFFGSA-N Sarsapogenine Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)C[C@H]4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 GMBQZIIUCVWOCD-WWASVFFGSA-N 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N Sildenafil Natural products CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000012902 lepidium meyenii Nutrition 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 231100000872 sexual dysfunction Toxicity 0.000 description 2
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 2
- 229940094720 viagra Drugs 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 241000554155 Andes Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000220284 Crassulaceae Species 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 235000003325 Ilex Nutrition 0.000 description 1
- 241000209035 Ilex Species 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 206010024421 Libido increased Diseases 0.000 description 1
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000000719 Prunus africana Nutrition 0.000 description 1
- 241000200478 Prunus africana Species 0.000 description 1
- 206010038419 Renal colic Diseases 0.000 description 1
- 241000362909 Smilax <beetle> Species 0.000 description 1
- RTMWIZOXNKJHRE-UHFFFAOYSA-N Tigogenin Natural products CC1COC2CC(C)(OC12)C3CCC4C5CCC6CC(O)CCC6(C)C5CCC34C RTMWIZOXNKJHRE-UHFFFAOYSA-N 0.000 description 1
- 241000190079 Turnera Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 235000016127 added sugars Nutrition 0.000 description 1
- 208000008445 altitude sickness Diseases 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000003029 clitoris Anatomy 0.000 description 1
- 230000001113 coital effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 235000018905 epimedium Nutrition 0.000 description 1
- 230000009986 erectile function Effects 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- TZJALUIVHRYQQB-XLRXWWTNSA-N icariin Chemical compound C1=CC(OC)=CC=C1C1=C(O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)C(=O)C2=C(O)C=C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C(CC=C(C)C)=C2O1 TZJALUIVHRYQQB-XLRXWWTNSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007334 memory performance Effects 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 231100000004 severe toxicity Toxicity 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 230000036332 sexual response Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- GMBQZIIUCVWOCD-NRBCCYJRSA-N spirostan-3-ol Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCC(O)CC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CCC(C)CO1 GMBQZIIUCVWOCD-NRBCCYJRSA-N 0.000 description 1
- 230000007103 stamina Effects 0.000 description 1
- 229930002600 steroidal saponin Natural products 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
Definitions
- An aphrodisiac herbal composition for a female individual, tablet or a capsule comprising the composition and a method for self- administration of the composition
- the present invention relates to an aphrodisiac herbal basic composition for a female individual.
- an oral aphrodisiac basic composition for the arousal of female sexual desire.
- an oral aphrodisiac basic composition in combination with extracts from additional herbs for further arousal of female sexual desire.
- a tablet or capsule including an aphrodisiac composition for a female.
- aphrodisiac composition comprising extracts or particulate material from the plants Epimedium Grandiflorum , Turnera diffusa var. aphrodisiaca , Ilex paraguariensis, and Sarsaparilla.
- Epimedium Grandiflorum is a slow-growing creeping plant with semi-evergreen leaves on erect wiry stems. Many cultures have reported that Epimedium Grandiflorum (Horny Goat Weed) supports increased libido, improved erectile function, and relief from menopausal discomfort. The leaves is used in traditional botanical medicine in China and Japan and although it has a history of traditional use for disorders of the kidneys, joints, liver, back and knees, its principle use is as an aphrodisiaca. However no meaningful clinical evidence has been presented in support of this use.
- Turnera diffusavar. ⁇ phrodisi ⁇ c ⁇ is commonly known as Damiana and was used as an aphrodisiac in the ancient Mayan civilization.
- the Mexican Indians made a drink from the Damiana leaves, added sugar, and drank it for its purported power to enhance lovemaking.
- T he British Herbal Pharmacopoeia cites indications for the use of Turnera diffusavar. aphrodisiaca in anxiety neurosis with a predominant sexual factor, depression, nervous dyspepsia, atonic constipation, and coital inadequacy.
- Ilex p ⁇ r ⁇ gu ⁇ riensis is an evergreen tree also also known as mate or Yerba mate.
- Yerba mate is cultivated in many tropical countries to supply a world demand for its leaves.
- Yerba mate is used as a tonic, diuretic, and as a stimulant to reduce fatigue, improve appetite, and aid gastric function in herbal medicine systems throughout South America.
- Yerba mate stimulates the nervous and muscular systems and hence, can be used for digestive problems, renal colic, neurasthenia, depression, and obesity.
- Phamacopoeia (1996) indicate the possibility for the treatment of fatigue, weight loss, and headaches.
- Sarsaparilla is a brambled, woody vine the long root of which was used by herbalists for treatment of e.g. rheumatism, cancer and skin diseases in ancient Mexico.
- Sarsaparilla contains steroidal saponins, such as sarsaponin or sarsasapogenin, which may mimic the action of some human hormones, e.g. pro ⁇ gesterone. To the knowledge of this inventor this property remains undocumented.
- Sarsaparilla root has been chewed by male Central and Southern Americans for sexual impotence and is used as an ingredient in commercial herbal preparations for libido en ⁇ hancement.
- U.S. Patent nr. 6,444,237 disclose an aphrodisiac composition of herbal in ⁇ gredients.
- the composition is comprised of extracts taken from Crataegus monogyna berry, Turnera diffusa, Pfaffla paniculata, Ginkgo biloba, Pygeum africanum, and gin- senosides extract, which are combined with L-arginine, L-glutamic acid and L- theanine in amounts effective to produce sexual desire.
- About 15 g of the composition and a flavouring agent is dissolved in water and ingested.
- the final agent includes a large number of ingredients to obtain the intended sexual stimulation effect and moreover a huge amount of agent must be ingested which is inconvenient for the user.
- composition may further comprise an extracts or particulate material from at least one additional second plant.
- said additional second plant can be Ginkgo biloba L. Extract from the dried leaf of Ginkgo biloba L has been recognized to have several pharmacological effects, such as e.g. improvement of hypoxic tolerance in the cerebral tissue, increased memory performance and learning capacity and improvement of blood flow in the region of microcirculation. Recent research have investigated Ginkgo biloba L benefits in patients suffering from anti- depression-induced sexual dysfunction [Cohen, A.J. and B. Bartlik. 1998. ' Ginkgo Biloba for antidepressant-induced sexual dysfunction', J. Sex Marital. Ther. 24(2): 139-143].
- said additional second plant can be Eurycoma longifolia Jack, which is also known under its commercial name Tongkat AIi.
- Eurycoma longifolia Jack is a tall shrub-tree found in the Malyasian canyon. The root has been utilized as aphrodisiac for males.
- the effects of extracts from the root of Eurycoma longifolia Jack were studied on the libido of sexually experienced male rats after dosing them with 200, 400 and 800 mg/kg body weight twice daily of different fractions of E. longifolia Jack for 10 days. Results showed that E. longifolia Jack produced a dose-dependent increase in mounting frequency of the treated male animals.
- the study provides evidence that E.
- longifolia Jack is a potent stimulator of sexual arousal in sexually vigorous male rats in the absence of feedback from genital sensation. [Hooi Hoon ANG and Meng Kwoon SIM; Eurycoma longifolia Jack enhances libido in sexually experienced male rats; Exp. Anim. 46(4), 287-290, 1997]. No clinical evidence is disclosed for female animals.
- This second embodiment constitutes a preferred alternative to the above-mentioned compositions and is preferred by many women.
- said additional second plant can be Rhodiola rosea L..
- Rhodiola rosea L. is also known as 'golden root' or 'roseroot' and belongs to the plant family Crassulaceae .
- the root were used to increase physical endurance, work productivity, longevity, resistance to high altitude sickness, and to treat fatigue, depression, anaemia, impotence, gastrointestinal ailments, infections, and nervous system disorders.
- a summary of these ancient uses is found in Herbal Gram. 2002; vol. 56, p 40-52; Journal of American Botanical Council; Rhodiola rosea: A Phytomedicinal Overview; Richard P. Brown, Patricia L. Gerbarg, and Zakir Ramazanov.
- said additional second plant can be Tribulus terrestris , which has long been used in the traditional Chinese and Indian systems of medicine for the treatment of various ailments and is claimed to improve sexual functions in man. Extracts from the fruits are commercially used in variouscombinations with other sex-enhancing herbs than the ones used in the present invention.
- said additional second plant can be Lepidum meyenii, also known commercially as Maca. Extracts from the root of Maca has traditionally been used for centuries in the Andes to enhance fertility in humans and animals.
- Preferred amounts of extract or particulate material from the at least one additional second plant is between 10 - 30 mg of Ginkgo biloba L, preferably from the leaves of Ginkgo biloba L, between 10 - 30 mg of Eurycoma longifolia Jack, preferably from the root of Eurycoma longifolia Jack, between 30 - 40 mg of Rhodiola roesea L., preferably from the root of Rhodiola roesea L., between 10 - 50 mg of Tribulus terrestris, preferably from the fruits of Tribulus terrestris and between 10 - 50 mg of Lepidum meyenii, preferably from the root of Lepidum meyenii.
- novel herbal basic compositions according to the present invention have proved its superiority as a female aphrodisiac as will be evident from the enclosed Examples.
- extract or particulate material from Erythroxylum catuaba is included in the composition it is preferred to include 400 - 1000 mg extract or particulate material from the bark of Erythroxylum catuaba .
- extract or particulate material from Eriosema kraussianum is included in the composition it is preferred to include 300 - 400 mg extract or particulate material from the rootstock of Eriosema kraussianum .
- At least one additive such as a filling agent and/ or a flavouring agent and/or a vitamin.
- a preferred filling agent is lactose, as commonly used as bulk material in tablets.
- the filler serves for providing the composition with a suitable appearance. Any vitamin can be included in the composition within the scope of the present invention id desired.
- Some herbal extracts have an unpleasant taste, which can be camouflaged by means of a flavouring agent to improved comfort for the woman during oral intake.
- composition can be pressed into tablets or be encapsulated using techniques known to the person skilled in the art.
- a tablet may have a basic weight of 1 g with a content of the active ingredients represented by the inventive basic composition of herbal extracts in a total amount of 650 mg.
- a recommended prescription is 4 times 650 mg active basic herbal composition taken orally at least 1 hour before sexual activity.
- the advantage of sexual desire will sustain during approximately 48 hours after oral ingestion. No special reasons are needed before start of treatment.
- the composition according to the present invention treatment is a short acute treatment. No permanent inexpedient increase in the oestrogenic level is released and consequently the women overall hormon balance remains substantially unaffected in the long term.
- the various aphrodisiac herbal compositions according to the present invention induce a widespread feeling of vigour, sexual attraction and increased sexual pleasure.
- Female test persons expired an increased blood circulation to the clitoris and increased stamina and sex drive.
- Group B (24 test persons) received four placebo capsules per 24 hours each containing 650 mg lactose (total weight corresponding to the total weight of basic composition given to Group A). None of the test persons had expressed sexual problems. No additives were included in any of the capsules.
- Example 2 Comparative test study of basic composition + extract from Ery ⁇ throxylum catuaba [49] Extract from the bark of Erythroxylum catuaba was obtained from King's College
- Example 1 and in addition two capsules per 24 hours containing 600 mg extract from
- Example 1 [52] Immediately after expiry of the 48-hour test period 67 % of the test persons confirmed their experience of improved aphrodisiac effect of the combined composition in relation to the effect of the basic composition. [53] Example 3: Comparative test study of basic composition + extract from the root of
- Eriosema kraussianum Extract from the root from Eriosema kraussianum was obtained from King's
- Example 1 and in addition two capsules containing 200 mg extracted kraussianone (1)
- the kraussianone nomenclature is the one established and used in ' Pyrano- isoflavones with erectile-dysfunction activity from Eriosema kraussianum ' ; Phyto- chemistryVol. 59, Iss. 7, April 2002, pp. 139-1 Al by Siegfried E. Drewes, Marion M.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A female aphrodisiac herbal basic composition serves for natural treatments suffering from lack of sexual desire an arousal disorders. The basic composition comprises extracts or particulate material from the plants Epimedium Grandiflorum, Turnera diffusa var.aphrodisiaca, Ilex paraguariensis, and Sarsaparilla and optionally an extract or particulate material from at least one additional second plant selected from the group of plants comprising Ginkgo biloba L, Eurycoma longifolia Jack, Rhodiola rosea L., Tribulus terrestris,Lepidum meyenii,Erythroxylum catuaba and Eriosema kraussianum . The composition brings back incentive to unhappy rela-tionships an offers a herbal composition as an alternative to pharmaceutical treatment.
Description
Description
An aphrodisiac herbal composition for a female individual, tablet or a capsule comprising the composition and a method for self- administration of the composition
[1] The present invention relates to an aphrodisiac herbal basic composition for a female individual.
[2] During the years focus has been put on the male sexuality, which has been in¬ tensively investigated. The treatment of erectile dysfunction has been the subject of many studies and proposed treatments, one of them being VIAGRA® .
[3] Numerous male sexual enhancement drugs or pills has been developed and are commercially available today. In the past years also a few female products have been developed with the intention to regulate hormone levels, increase female sex drive, increase circulation and relieve anxiety. Such commonly known products are e.g. clitoris-stimulating creams for topical application in relation to or just before sexual in¬ tercourse. In addition a few oral compositions including amino acids are offered for sale via the Internet. Intake of large amounts of amino acids may have a negative influence on the health and should be avoided.
[4] Many women experience a loss of sexual vitality at some time in their lives.
External factors such as stress and fatigue may contribute to the decline in sexual interest, which often lead to problems in the relationship or even misconduct. However t oday's emancipated woman attempt to overcome this problem and seeks a solution to improved sexual pleasure and experience; and through the past few years the demand for female sexual desire promoting means have increased.
[5] In a first aspect according to the present invention is provided an oral aphrodisiac basic composition for the arousal of female sexual desire.
[6] In a second aspect according to the present invention is provided an oral aphrodisiac basic composition in combination with extracts from additional herbs for further arousal of female sexual desire.
[7] In a third aspect according to the present invention is provided a tablet or capsule including an aphrodisiac composition for a female.
[8] This is uniquely achieved according to the present invention by means of an aphrodisiac composition comprising extracts or particulate material from the plants Epimedium Grandiflorum , Turnera diffusa var. aphrodisiaca , Ilex paraguariensis, and Sarsaparilla.
[9] An aphrodisiac composition within the context of this invention arouses sexual desire.
[10] Epimedium Grandiflorum is a slow-growing creeping plant with semi-evergreen leaves on erect wiry stems. Many cultures have reported that Epimedium Grandiflorum (Horny Goat Weed) supports increased libido, improved erectile function, and relief from menopausal discomfort. The leaves is used in traditional botanical medicine in China and Japan and although it has a history of traditional use for disorders of the kidneys, joints, liver, back and knees, its principle use is as an aphrodisiaca. However no meaningful clinical evidence has been presented in support of this use.
[11] Turnera diffusavar. αphrodisiαcα is commonly known as Damiana and was used as an aphrodisiac in the ancient Mayan civilization. The Mexican Indians made a drink from the Damiana leaves, added sugar, and drank it for its purported power to enhance lovemaking. T he British Herbal Pharmacopoeia cites indications for the use of Turnera diffusavar. aphrodisiaca in anxiety neurosis with a predominant sexual factor, depression, nervous dyspepsia, atonic constipation, and coital inadequacy.
[12] Ilex pαrαguαriensis is an evergreen tree also also known as mate or Yerba mate.
The stiff and leathery leaves are used medicinally and as a natural, refreshing tea beverage throughout South America. Today Yerba mate is cultivated in many tropical countries to supply a world demand for its leaves. Yerba mate is used as a tonic, diuretic, and as a stimulant to reduce fatigue, improve appetite, and aid gastric function in herbal medicine systems throughout South America. It has also been suggested that Yerba mate stimulates the nervous and muscular systems and hence, can be used for digestive problems, renal colic, neurasthenia, depression, and obesity. Also t he British Herbal Phamacopoeia (1996) indicate the possibility for the treatment of fatigue, weight loss, and headaches.
[13] Smilax spp. or Sarsaparilla is a brambled, woody vine the long root of which was used by herbalists for treatment of e.g. rheumatism, cancer and skin diseases in ancient Mexico. Sarsaparilla contains steroidal saponins, such as sarsaponin or sarsasapogenin, which may mimic the action of some human hormones, e.g. pro¬ gesterone. To the knowledge of this inventor this property remains undocumented. Sarsaparilla root has been chewed by male Central and Southern Americans for sexual impotence and is used as an ingredient in commercial herbal preparations for libido en¬ hancement. However, their exist no evidence of the recipe of these preparations and clinical evidence of the effects. Also, a considerable amount of 2-4 grams must be ingested three times per day [Blumenthal M, Busse WR, Goldberg A, et al. (eds). The Complete Commission E Monographs: Therapeutic Guide to Herbal Medicines. Boston, MA: Integrative Medicine Communications, 1998, 372-3].
[14] U.S. Patent nr. 6,444,237 disclose an aphrodisiac composition of herbal in¬ gredients. The composition is comprised of extracts taken from Crataegus monogyna berry, Turnera diffusa, Pfaffla paniculata, Ginkgo biloba, Pygeum africanum, and gin-
senosides extract, which are combined with L-arginine, L-glutamic acid and L- theanine in amounts effective to produce sexual desire. About 15 g of the composition and a flavouring agent is dissolved in water and ingested. The final agent includes a large number of ingredients to obtain the intended sexual stimulation effect and moreover a huge amount of agent must be ingested which is inconvenient for the user.
[15] The present inventor has surprisingly found that the novel basic combination of extracts or particulate material from parts of the above-mentioned plants have a better and synergistic aphrodisiac effect than obtained with known herbal compositions or with the extracts or the plants alone. Comprehensive studies in support of this have been performed at King's College, University of London and will be further discussed in Example 1 below.
[16] Advantageously, the composition may further comprise an extracts or particulate material from at least one additional second plant.
[17] In a first embodiment according to the present invention said additional second plant can be Ginkgo biloba L. Extract from the dried leaf of Ginkgo biloba L has been recognized to have several pharmacological effects, such as e.g. improvement of hypoxic tolerance in the cerebral tissue, increased memory performance and learning capacity and improvement of blood flow in the region of microcirculation. Recent research have investigated Ginkgo biloba L benefits in patients suffering from anti- depression-induced sexual dysfunction [Cohen, A.J. and B. Bartlik. 1998. ' Ginkgo Biloba for antidepressant-induced sexual dysfunction', J. Sex Marital. Ther. 24(2): 139-143]. It was found that of 63 subjects, 33 women and 30 men, the women were more responsive to the sexually enhancing effects than the men. The relative success rates were 91% for the women compared to 76% for the men. The ginkgo (product brand not noted) was given at a dosage range of 60 to 120 mg twice daily, within the normal range for the usual applications of ginkgo. A positive effect on all four phases of the sexual response cycle: desire, excitement (erection and lubrication), orgasm, and resolution (afterglow) were reported. A daily intake as in the present study has a number of disadvantages for the patient. E.g. there is an annoying risk that the sexual organs are permanently stimulated. However, the above findings have encouraged the present inventor in the search for an improved aphrodisiac composition.
[18] In a second embodiment according to the present invention said additional second plant can be Eurycoma longifolia Jack, which is also known under its commercial name Tongkat AIi. Eurycoma longifolia Jack is a tall shrub-tree found in the Malyasian jungle. The root has been utilized as aphrodisiac for males. The effects of extracts from the root of Eurycoma longifolia Jack were studied on the libido of sexually experienced male rats after dosing them with 200, 400 and 800 mg/kg body
weight twice daily of different fractions of E. longifolia Jack for 10 days. Results showed that E. longifolia Jack produced a dose-dependent increase in mounting frequency of the treated male animals. The study provides evidence that E. longifolia Jack is a potent stimulator of sexual arousal in sexually vigorous male rats in the absence of feedback from genital sensation. [Hooi Hoon ANG and Meng Kwoon SIM; Eurycoma longifolia Jack enhances libido in sexually experienced male rats; Exp. Anim. 46(4), 287-290, 1997]. No clinical evidence is disclosed for female animals. This second embodiment constitutes a preferred alternative to the above-mentioned compositions and is preferred by many women.
[19] In a third embodiment according to the present invention said additional second plant can be Rhodiola rosea L.. Rhodiola rosea L. is also known as 'golden root' or 'roseroot' and belongs to the plant family Crassulaceae . Traditionally, the root were used to increase physical endurance, work productivity, longevity, resistance to high altitude sickness, and to treat fatigue, depression, anaemia, impotence, gastrointestinal ailments, infections, and nervous system disorders. A summary of these ancient uses is found in Herbal Gram. 2002; vol. 56, p 40-52; Journal of American Botanical Council; Rhodiola rosea: A Phytomedicinal Overview; Richard P. Brown, Patricia L. Gerbarg, and Zakir Ramazanov. This summary also describes a study of /?, rosea extract in women suffering from amenorrhea concluding that R. rosea is able to restore normal menses and increase tendency to become pregnant. The inventors of the present ap¬ plication know no report or clinical evidence of Rhodiola roseaL. having an aphrodisiac effect.
[20] In a fourth embodiment according to the present invention said additional second plant can be Tribulus terrestris , which has long been used in the traditional Chinese and Indian systems of medicine for the treatment of various ailments and is claimed to improve sexual functions in man. Extracts from the fruits are commercially used in variouscombinations with other sex-enhancing herbs than the ones used in the present invention.
[21] In a fifth embodiment according to the present invention said additional second plant can be Lepidum meyenii, also known commercially as Maca. Extracts from the root of Maca has traditionally been used for centuries in the Andes to enhance fertility in humans and animals.
[22] Optionally extracts or particulate material from Erythroxylum catuaba , which is a vigorous growing tree in the northern part of Brazil can be added. A bark decoction is known to be used for sexual impotency and weakness by the male Brazilian Indians but the prior art teachings lack clinical discussions and further evidence. It has been found by the inventor that some women have preference for this embodiment of the present invention rather than the basic herbal composition.
[23] As a variation extract or particulate material from Eriosema kraussianum may be included in the composition. Five pyrano-isoflavones have been isolated from the rootstock of Eriosema kraussianum N. E. Br (Papilionaceae). The most active of the compounds had an activity of 75% of that found in Viagra® in the erectile dysfunction test on rabbit penile smooth muscle. [Siegfried E. Drewes, Marion M. Horn, Orde Q. Munro, Jabu T. B. Dhlamini, J. J. Marion Meyer and N. Christopher Rakuambo; Pyrano-isoflavones with erectile-dysfunction activity from Eriosema kraussianum; PhytochemistryVol. 59, Iss. 7, April 2002, pp. 739-747]. No comparable study has been made for the female. This embodiment constitutes a preferred alternative to the compositions above and is preferred by many.
[24] Preferred amounts of extract from the plants of the basic composition is between
200 - 400 mg from Epimedium Grandiflorum, preferably from the leaves of Epimedium Grandiflorum, between 40 - 60 mg from Turnera diffusa var. aphrodisiaca , preferably from the leaves of Turnera diffusa var. aphrodisiaca, 40 - 60 mgllex paraguariensis, preferably from the leaves of Ilex paraguariensis, and 3 - 6 mg from Sarsaparilla, preferably from the root of Sarsaparilla.
[25] Preferred amounts of extract or particulate material from the at least one additional second plant is between 10 - 30 mg of Ginkgo biloba L, preferably from the leaves of Ginkgo biloba L, between 10 - 30 mg of Eurycoma longifolia Jack, preferably from the root of Eurycoma longifolia Jack, between 30 - 40 mg of Rhodiola roesea L., preferably from the root of Rhodiola roesea L., between 10 - 50 mg of Tribulus terrestris, preferably from the fruits of Tribulus terrestris and between 10 - 50 mg of Lepidum meyenii, preferably from the root of Lepidum meyenii.
[26] The novel herbal basic compositions according to the present invention have proved its superiority as a female aphrodisiac as will be evident from the enclosed Examples.
[27] When extract or particulate material from Erythroxylum catuaba is included in the composition it is preferred to include 400 - 1000 mg extract or particulate material from the bark of Erythroxylum catuaba .
[28] When extract or particulate material from Eriosema kraussianum is included in the composition it is preferred to include 300 - 400 mg extract or particulate material from the rootstock of Eriosema kraussianum .
[29] It may be advantageous to include at least one additive, such as a filling agent and/ or a flavouring agent and/or a vitamin. A preferred filling agent is lactose, as commonly used as bulk material in tablets. The filler serves for providing the composition with a suitable appearance. Any vitamin can be included in the composition within the scope of the present invention id desired.
[30] Some herbal extracts have an unpleasant taste, which can be camouflaged by
means of a flavouring agent to improved comfort for the woman during oral intake.
[31 ] The composition can be pressed into tablets or be encapsulated using techniques known to the person skilled in the art. As an example, a tablet may have a basic weight of 1 g with a content of the active ingredients represented by the inventive basic composition of herbal extracts in a total amount of 650 mg.
[32] A recommended prescription is 4 times 650 mg active basic herbal composition taken orally at least 1 hour before sexual activity. The advantage of sexual desire will sustain during approximately 48 hours after oral ingestion. No special reasons are needed before start of treatment. In contrast to the few known oral compositions the composition according to the present invention treatment is a short acute treatment. No permanent inexpedient increase in the oestrogenic level is released and consequently the women overall hormon balance remains substantially unaffected in the long term.
[33] No reports have been found on severe toxicity and the inventor of the present invention considers the present aphrodisiac herbal composition as extremely safe products.
[34] The various aphrodisiac herbal compositions according to the present invention induce a widespread feeling of vigour, sexual attraction and increased sexual pleasure. Female test persons expired an increased blood circulation to the clitoris and increased stamina and sex drive.
[35] All components used for manufacturing the basic composition have been obtained from Dansk farmaceutisk industri A/S (Danish Pharmaceutical Industries Ltd), Indus- triparken 4, 2750 Ballerup, Denmark.
[36] All tests were performed in co-operation with King's College London, University of London, Strand, London WC2R 2LS, England, United Kingdom under medical su¬ pervision.
[37]
EXAMPLES
[38] Example 1 : Test study of basic composition
[39] 48 voluntary healthy women aged between 25 and 60 years (mean age: 36,5 year) were randomised into two groups. Group A (24 test persons) received four capsules per 24 hours, each capsule contained 650 mg of the active basic composition [300 mg extract from the leaves of Epimediwn Grandiflorum, 35 mg extract from the root of Rhodiola rosea L., 50 mg extract from the leaves of Turnera diffusa vai.aphrodisiaca, 50 mg extract from the leaves of Ilex paraguariensis, 60 mg extract from the leaves of Ginkgo biloba L. and 5 mg extract from the root of Sarsaparilla], and Group B (24 test persons) received four placebo capsules per 24 hours each containing 650 mg lactose (total weight corresponding to the total weight of basic composition given to Group A). None of the test persons had expressed sexual problems. No additives were included in
any of the capsules.
[40] The tests persisted in 48 hours. After expiry of the test period the test persons filled in a questionnaire. The results is presented in Table 1 below: [41] Table 1
[42] The difference between the Group A and B has a statistical level of significance (0,01). [43] It should be noted that a completely objective answer to the questions put to the test persons are difficult to achieve. Some of the test persons of Group B also observed a level of effect. One explanation to this could be the intensified focus on the sex life of the persons involved. Test persons informing her partner of the test expired clearly improved effect of the placebo treatment. This finding has not been substantiated sta¬ tistically. However, the general indication is that the overall effect of the compositions surpasses the sum of the effect of the single constituents if administered alone, thereby indicating a synergistic reaction. Although not fully explainable one reason for the synergistic result is believed by the researcher to be occasioned by the effect of the composition on certain brain receptors.
[44] In Group A two persons reported nausea and four persons reported headache
during the test period of 48 hours. However, neither nausea nor headache was regarded as side effects from the herbal basic composition. [45] In Group B three persons noted transitory nausea related to the placebo intake, three persons noted headache and one person noted mild dyspectic nuisance. [46] The present test study is a clear indication that the herbal basic composition constitutes an attractive aphrodisiac for the female individual. [47] The tests of the following Examples 2, 3 and 4 were performed with 14 days intervals.
[48] Example 2: Comparative test study of basic composition + extract from Ery¬ throxylum catuaba [49] Extract from the bark of Erythroxylum catuaba was obtained from King's College
London, University of London, Strand, London WC2R 2LS, England, United
Kingdom. [50] The 24 test persons of Group A of Example 1 participated in the additional test study in which the aphrodisiac effect of the herbal basic composition was compared with the aphrodisiac effect of the herbal basic composition combined with extract from the bark from Erythroxylum catuaba . [51] Each person in Group A now received the same dose basic composition as in
Example 1 and in addition two capsules per 24 hours containing 600 mg extract from
Erythroxylum catuaba . Other test conditions were aimed at being the same as in
Example 1. [52] Immediately after expiry of the 48-hour test period 67 % of the test persons confirmed their experience of improved aphrodisiac effect of the combined composition in relation to the effect of the basic composition. [53] Example 3: Comparative test study of basic composition + extract from the root of
Eriosema kraussianum [54] Extract from the root from Eriosema kraussianum was obtained from King's
College London, University of London, Strand, London WC2R 2LS, England, United
Kingdom . [55] The 24 test persons of Group A of Example 1 participated in the additional test study in which the aphrodisiac effect of the herbal basic composition was compared with the aphrodisiac effect of the herbal basic composition combined with extract from the root from Eriosema kraussianum . [56] Each person in Group A now received the same dose basic composition as in
Example 1 and in addition two capsules containing 200 mg extracted kraussianone (1)
+ 200 mg extracted kraussianone (2) per 24 hours from the root of Eriosema kraussianum . The other test conditions were aimed at being the same as in Example 1.
[The kraussianone nomenclature is the one established and used in ' Pyrano-
isoflavones with erectile-dysfunction activity from Eriosema kraussianum ' ; Phyto- chemistryVol. 59, Iss. 7, April 2002, pp. 139-1 Al by Siegfried E. Drewes, Marion M.
Horn, Orde Q. Munro, Jabu T. B. Dhlamini, J. J. Marion Meyer and N. Christopher
Rakuambo]. [57] Immediately after expiry of the 48-hour test period 71 % of the test persons confirmed their experience of improved aphrodisiac effect of the combined composition in relation to the effect of the basic composition. [58] Example 4: Comparative test study of basic composition + extract from the root of
Eurycoma longifolia Jack [59] Extract from the root of Eurycoma longifolia Jack was obtained from Phytes
Biotek Sdn. Bhd, Lot 21, Jalan Ul/19 Section Ul, Hicom-Glenmarie Industrial Park,
40150 Shah Alam, Selangor, MaIy sia. [60] The 24 test persons of Group A of Example 1 participated in the additional test study in which the aphrodisiac effect of the herbal basic composition was compared with the aphrodisiac effect of the herbal basic composition combined with extract from the root of Eurycoma longifolia Jack. [61] Each person in Group A now received the same dose basic composition and two capsules per 24 hours containing 20 mg extract from the root of Eurycoma longifolia
Jack . Other test conditions were aimed at being the same as in Example 1. [62] Immediately after expiry of the 48-hour test period 79 % of the test persons confirmed their experience of improved aphrodisiac effect of the combined composition in relation to the effect of the basic composition. [63] The inventive compositions and combined compositions are all attractive natural treatments for female individuals suffering from lack of sexual desire an arousal disorders. The invention can bring incentive back to unhappy relationships. [64] The treatment of any female animal other than the human being is also considered within the scope of the present invention.
Claims
[1] A female aphrodisiac herbal basic composition comprising extracts or particulate matter from the plants Epimedium Grandiflorum, Turnera diffusa var. aphrodisiaca , Ilex paraguariensis and Sarsaparilla.
[2] A composition according to claim 1, characterised in that the composition further comprises an extract or a particulate matter from at least one additional second plant selected from the group of plants comprising Ginkgo biloba L, Eurycoma longifolia Jack, Rhodiola rosea L, Tribulus terrestris,Lepidum meyenii,Erythroxylum catuaba andEriosema kraussianum.
[3] A composition according to claim 1, characterised in that an effective amount per 24 hours of extracts or particulate matter from Epimedium Grandiflorum is between 200 - 400 mg, from Turnera diffusa \ ax. aphrodisiaca between 40 - 60 mg, from Ilex paraguariensis between 40 - 60 mg and from Sarsaparilla between 3 - 6 mg.
[4] A composition according to claim 2 or 3, characterised in that the effective amount per 24 hours of extract or particulate material of the at least one additional second plant is between 50 - 70 mg of Ginkgo biloba L, between 10 - 30 mg of Eurycoma longifolia Jack, between 30 - 40 mg of Rhodiola roesea L. is, between 10 - 50 mg of Tribulus terrestris , between 10 - 50 mg of Lepidum meyenii, between 400 - 1000 mg of Erythroxylum catuaba, and between 300 - 400 mg of Eriosema kraussianum.
[5] A composition according to any of the preceding claims 1 - 3, characterised in that the composition further comprises at least one additive, said additive being a filling agent and/or a flavouring agent and/or a vitamin.
[6] A tablet or a capsule comprising the composition according to any of the claims
1 - 5.
[7] A method for enhancing sexual attraction comprising female self-administration of the composition according to any of the claims 1 - 5 at least one hour before sexual activity.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200401281 | 2004-08-25 | ||
| DKPA200401281 | 2004-08-25 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2006021930A2 true WO2006021930A2 (en) | 2006-03-02 |
| WO2006021930A3 WO2006021930A3 (en) | 2006-05-26 |
Family
ID=35677413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/IB2005/052768 WO2006021930A2 (en) | 2004-08-25 | 2005-08-24 | Aphrodisiac herbal composition for a female comprising epimedium grandiflorum, turnera diffusa var. aphrodisiaca, ilex paraguariensis and smilax spp |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2006021930A2 (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008098329A2 (en) * | 2007-02-13 | 2008-08-21 | Aché Laboratórios Farmacêuticos S/A | Pharmaceutical composition, pharmaceutical product, obtaining processes of pharmaceutical compounds and use of such compounds for treating erectile dysfunction |
| US7906159B2 (en) | 2008-04-17 | 2011-03-15 | Vivien Chou | Herbal compositions and methods for enhancing vital energy and athletic performance |
| ES2386859A1 (en) * | 2011-02-07 | 2012-09-03 | Eduardo Antonio Gómez De Diego | Natural composition to increase the vigor. (Machine-translation by Google Translate, not legally binding) |
| CN103156191A (en) * | 2013-03-18 | 2013-06-19 | 陈树杰 | Health-care food for promoting man testosterone secretion |
| ES2462553A1 (en) * | 2014-01-16 | 2014-05-23 | Gepnes Hattrick Sl | Composition for improvement of sexual well-being (Machine-translation by Google Translate, not legally binding) |
| US10226418B2 (en) | 2014-05-12 | 2019-03-12 | Susie Q, Ltd. | Arginine-containing topical composition |
| IT201700115753A1 (en) * | 2017-10-13 | 2019-04-13 | Cristalfarma S R L | Supplement to alleviate the problems caused by aging in women |
| WO2020230011A1 (en) * | 2019-05-13 | 2020-11-19 | Guglielmo Buonamici | Human nutraceutical supplement |
| IT201900009018A1 (en) * | 2019-06-14 | 2020-12-14 | Carmen Iannella | ALCOHOLIC BEVERAGE |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002078746A1 (en) * | 2001-03-30 | 2002-10-10 | Altaffer, Paulo | Novel chocolate composition as delivery system for nutrients and medications |
| WO2003037246A2 (en) * | 2001-07-17 | 2003-05-08 | Integrated Chinese Medicine Holdings Ltd. | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| WO2003047610A1 (en) * | 2001-12-03 | 2003-06-12 | Herturn, L.L.C. | Composition and method to increase female sexual desire and sexual satisfaction |
| US20030203053A1 (en) * | 1998-04-03 | 2003-10-30 | Wuh Hank C.K. | Method and composition for improving sexual fitness |
| WO2003094943A1 (en) * | 2002-05-10 | 2003-11-20 | Indena S.P.A. | Formulations useful in the treatment of male and female impotence |
-
2005
- 2005-08-24 WO PCT/IB2005/052768 patent/WO2006021930A2/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030203053A1 (en) * | 1998-04-03 | 2003-10-30 | Wuh Hank C.K. | Method and composition for improving sexual fitness |
| WO2002078746A1 (en) * | 2001-03-30 | 2002-10-10 | Altaffer, Paulo | Novel chocolate composition as delivery system for nutrients and medications |
| WO2003037246A2 (en) * | 2001-07-17 | 2003-05-08 | Integrated Chinese Medicine Holdings Ltd. | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
| WO2003047610A1 (en) * | 2001-12-03 | 2003-06-12 | Herturn, L.L.C. | Composition and method to increase female sexual desire and sexual satisfaction |
| WO2003094943A1 (en) * | 2002-05-10 | 2003-11-20 | Indena S.P.A. | Formulations useful in the treatment of male and female impotence |
Non-Patent Citations (1)
| Title |
|---|
| MELETIS, C.D.: "Nature's True Aphrodisiacs: Vital Health Factors For Men and Women" ALTERNATIVE AND COMPLEMENTARY THERAPIES, vol. 6, no. 4, 2000, pages 207-211, XP008062024 * |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008098329A2 (en) * | 2007-02-13 | 2008-08-21 | Aché Laboratórios Farmacêuticos S/A | Pharmaceutical composition, pharmaceutical product, obtaining processes of pharmaceutical compounds and use of such compounds for treating erectile dysfunction |
| WO2008098329A3 (en) * | 2007-02-13 | 2009-02-05 | Ache Lab Farmaceuticos Sa | Pharmaceutical composition, pharmaceutical product, obtaining processes of pharmaceutical compounds and use of such compounds for treating erectile dysfunction |
| US7906159B2 (en) | 2008-04-17 | 2011-03-15 | Vivien Chou | Herbal compositions and methods for enhancing vital energy and athletic performance |
| US8119170B2 (en) | 2008-04-17 | 2012-02-21 | Wen Hsien Chou | Herbal compositions and methods for enhancing vital energy and athletic performance |
| ES2386859A1 (en) * | 2011-02-07 | 2012-09-03 | Eduardo Antonio Gómez De Diego | Natural composition to increase the vigor. (Machine-translation by Google Translate, not legally binding) |
| CN103156191A (en) * | 2013-03-18 | 2013-06-19 | 陈树杰 | Health-care food for promoting man testosterone secretion |
| ES2462553A1 (en) * | 2014-01-16 | 2014-05-23 | Gepnes Hattrick Sl | Composition for improvement of sexual well-being (Machine-translation by Google Translate, not legally binding) |
| US10226418B2 (en) | 2014-05-12 | 2019-03-12 | Susie Q, Ltd. | Arginine-containing topical composition |
| IT201700115753A1 (en) * | 2017-10-13 | 2019-04-13 | Cristalfarma S R L | Supplement to alleviate the problems caused by aging in women |
| WO2019073433A1 (en) * | 2017-10-13 | 2019-04-18 | Cristalfarma S.R.L. | Supplement for mitigating woman's disorders caused by ageing |
| JP2020536590A (en) * | 2017-10-13 | 2020-12-17 | クリスタルファルマ・ソチエタ・ア・レスポンサビリタ・リミタータ | Supplements to relieve women's disabilities caused by aging |
| US11433109B2 (en) | 2017-10-13 | 2022-09-06 | Cristalfarma S.R.L. | Supplement for mitigating woman's disorders caused by ageing |
| US12005075B2 (en) | 2017-10-13 | 2024-06-11 | Cristalfarma S.R.L. | Supplement for mitigating woman's disorders caused by ageing |
| WO2020230011A1 (en) * | 2019-05-13 | 2020-11-19 | Guglielmo Buonamici | Human nutraceutical supplement |
| IT201900009018A1 (en) * | 2019-06-14 | 2020-12-14 | Carmen Iannella | ALCOHOLIC BEVERAGE |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006021930A3 (en) | 2006-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Khare | Indian herbal remedies: rational Western therapy, ayurvedic, and other traditional usage, Botany | |
| WO2006021930A2 (en) | Aphrodisiac herbal composition for a female comprising epimedium grandiflorum, turnera diffusa var. aphrodisiaca, ilex paraguariensis and smilax spp | |
| CA2563952C (en) | Uses of the pregnane glycosides in the treatment/management of obesity, obesity-related and other disorders | |
| JP2004537577A (en) | (Rhizo) phosphatidylserine-containing preparation for prevention and treatment of stress state in warm-blooded animals | |
| CN103356751B (en) | The extractive composition of sexual function improving, promotion male genitals regrowth | |
| CN109316528B (en) | Medicine for treating male erectile dysfunction and preparation method thereof | |
| CN102716315A (en) | Kidney yang tonifying health care medicinal liquor and preparation method thereof | |
| KR20100036820A (en) | The invigorate energy food which is made from herb medicine and the producing method thereof | |
| CN103494209B (en) | Maca composite health care medicine | |
| US20060269623A1 (en) | Herbal composition and method of use for promoting erections and treating erectile dysfunction in men | |
| KR100688252B1 (en) | Composition for improving male sexual function | |
| CN103142848B (en) | Anti-aging Chinese medicine preparation and preparation method thereof | |
| CN104489172A (en) | Acanthopanax health tea for improving immunity and preparation method thereof | |
| CN106177166A (en) | A kind of compositions with function of physical fatigue alleviation and preparation method thereof | |
| KR102180363B1 (en) | An anti-impotence formula comprising black sesame and yeast hydrolysate | |
| AU2003254759B2 (en) | New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits | |
| US20140227352A1 (en) | Oral aphrodisiac herbal composition and capsule | |
| RU2189243C1 (en) | Compositions "ginrosin" showing general tonic and adaptogenic effect | |
| JP2012180331A (en) | Oral ingestion medicine for inducement of early recovery of muscle damage | |
| US20050266096A1 (en) | New synergetic compositions of vitamins, minerals and trace-elements to stimulate the elimination of intra-cellular lipid deposits | |
| US11273191B2 (en) | Administering compositions for improved immune system functioning | |
| RU2659172C1 (en) | Combination of two cryoprotective collections for adaptation of human to cooling microclimate | |
| BG2526U1 (en) | A means for increasing sexual activity | |
| RU2161038C1 (en) | Medicinal species for alcohol withdrawal syndrome and alcohol addiction elimination | |
| RU2635373C1 (en) | Biologically active additive for increasing general working ability |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |